Non-therapeutic use of hyperbranched dextrins as a soothing agent

Abstract

The present invention relates to hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, for use as a soothing agent as well as in a method for preventing or reducing or eliminating reactions of the skin and / or the scalp and / or the oral mucous membranes.

Description

Description Title: NON-THERAPEUTIC USE OF HYPERBRANCHED DEXTRINS AS A SOOTHING AGENT. Technical field

[0001] The present invention relates to hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, for their use as a soothing agent as well as in a method for preventing or reducing or eliminating skin reactions and reactions of the oral mucous membranes. State of the art

[0002] The skin and oral mucosa constitute both a living anatomical barrier and an exchange zone between the body and its environment, the effectiveness of which determines the maintenance of a good homeostatic balance. The skin comprises a superficial layer consisting of the epidermis, made of keratinized epithelial cells, and deeper layers forming the dermis and hypodermis, and each of these layers has specific properties allowing the whole to react and adapt to the conditions of its environment. The oral mucosa is structured in a similar way to the skin, with the difference that it does not have a superficial layer made of keratinized epithelial cells, but on the contrary, its surface is made of non-keratinized epithelial cells.

[0003] Skin and oral mucosal reactions can be caused by the environment, for example, cold, UV radiation, friction, food or drinks, as well as by certain products and active ingredients present in cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary or domestic compositions. These skin reactions lead to a feeling of discomfort felt on the user's skin, scalp and oral mucosa, such as heating, tightness, tingling, itching, numbness. These skin reactions are increased on sensitive skin and scalps as well as on sensitive mucosa. Cosmetic treatments can relieve these feelings of discomfort linked to skin and oral mucosal reactions by a soothing effect when applying the cosmetic product.

[0004] There is therefore a need to identify soothing compounds that can also prevent, reduce and soothe skin and oral mucosal reactions generated by the environment or cosmetic products.

[0005] Some C-glycoside derivatives are known for their soothing properties and have been incorporated into cosmetic compositions. Examples include those described in document FR2902998. Summary

[0006] The applicant has demonstrated that a hyperbranched dextrin marketed under the reference Nutriose® HM 06 by Roquette, can soothe the sensations of heating and tightness caused by 20 hours of exposure of the skin of the forearms to sodium lauryl sulfate (SLS).

[0007] The present invention relates to the use of hyperbranched dextrins as a soothing agent.

[0008] The present invention also relates to the use of hyperbranched dextrins for preventing or reducing or eliminating skin reactions and / or reactions of the oral mucous membranes.

[0009] The present invention also relates to a method for non-therapeutic care of the skin and / or scalp and / or oral mucosa comprising the application of hyperbranched dextrins to the skin and / or scalp and / or oral mucosa.

[0010] The present invention also relates to cosmetic compositions comprising, in a cosmetically acceptable medium, hyperbranched dextrins.

[0011] These compositions are suitable for all skin types and are particularly intended for sensitive skin and / or scalp and sensitive oral mucous membranes. Detailed description

[0012] Hyperbranched dextrin

[0013] According to a first embodiment, the dextrins useful for the non-therapeutic use which is the subject of the present application are hyperbranched dextrins.

[0014] By "dextrin", the applicant means glucose polymers obtained from granular starch by pyroconversion, usually by the action of an acid in a generally dry medium, that is to say on granules in the form of dry solid particles, containing residual moisture imposed by the conditions of physical equilibrium at a given temperature and pressure. Thus, maltodextrins and pyrogenic dextrins fall within the general family of dextrins useful in the invention when they have been modified to be branched.

[0015] In the context of the invention, by "dextrin", the applicant also means glucose polymers resulting from the liquefaction or hydrolysis of starch by acid or enzymatic means and generally called "maltodextrin", "starch hydrolysate" or "glucose syrup", provided that these polymers have been additionally modified by chemical or enzymatic means, in particular by branching enzymes, to have glucosidic bonds between the anhydroglucose molecules, significantly different in terms of nature from those of the starch from which they are derived. Thus, maltodextrins, starch hydrolysates, glucose syrups and pyrogenic dextrins fall within the general family of dextrins useful for the invention provided that they differ in terms of carbohydrate bonds from the starch from which they are derived, including "atypical" bonds.

[0016] By "hyperbranched dextrin", the applicant means a "dextrin" having glucosidic bonds between the anhydroglucose molecules, significantly different in terms of nature and quantity, from those naturally constituting the starch from which it is derived. It contains glucosidic bonds between anhydroglucose molecules naturally present, the 1-6 bonds, but in greater quantity, and glucosidic bonds not naturally present in starch, called "atypical", the 1-3 and 1-2 bonds. Thus, a hyperbranched dextrin is a dextrin containing a large proportion of branching glucosidic bonds compared to the total number of glucosidic bonds present in said dextrin. The term "hyperbranched" can also be replaced by the term "highly branched".

[0017] By "high proportion" is meant a proportion of branching glucosidic bonds greater than or equal to 5% relative to the sum of branching glucosidic bonds and linear glucosidic bonds, preferably greater than or equal to 10%, more preferably greater than or equal to 20%, more preferably greater than or equal to 30%, more preferably greater than or equal to 40%, more preferably greater than or equal to 50%. Branching glucosidic bonds are bonds generating non-linear chains, in proportions greater than the normal values ​​of a native starch. The glucosidic bonds generating non-linear chains are the 1-6, 1-3, and 1-2 glucosidic bonds, as illustrated in Figure 1 [FIG 1]. The 1-3 and 1-2 bonds are the atypical glucosidic bonds.The normal values ​​for these bonds in a native starch are about 5% for the 1-6 bonds, and about 0% for the 1-2 and 1-3 bonds. The remainder is composed of the 1-4 glycosidic bonds, or about 95%. The 1-4 bond is a bond that creates a linear bond.

[0018] For the 1-6 glucosidic bonds, characteristic values ​​of the hyperbranched dextrins useful in the invention are values ​​greater than 5% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, preferably greater than or equal to 10%, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds and more preferably greater than or equal to 12% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and most preferably greater than or equal to 15% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0019] Thus, according to one embodiment, the hyperbranched dextrins comprise at least 5%, preferably at least 10%, preferably at least 12%, preferably at least 15% of 1-6 glucosidic bonds relative to the sum of the alpha 1-2, 1-3, 1-4 and 1-6 bonds.

[0020] For the 1-2 and 1-3 glucosidic bonds, the values ​​useful for the invention are values ​​greater than 1% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, preferably greater than or equal to 5% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and more preferably greater than or equal to 10% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0021] Thus, according to one embodiment, the hyperbranched dextrins comprise at least 1%, preferably at least 5%, preferably at least 10%, and preferably at least 20% of 1-2 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0022] According to one embodiment, the hyperbranched dextrins comprise at least 1%, preferably at least 5%, preferably at least 10% and preferably at least 20% of 1-3 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0023] For the 1-4 glucosidic bonds, the values ​​useful for the invention are values ​​less than 70%, preferably less than 60%, preferably less than 50%, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds and preferably between 42 and 50%, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0024] Thus, according to one embodiment, the hyperbranched dextrins comprise at most 70%, preferably at most 50% of 1-4 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0025] Preferably, the hyperbranched dextrins, preferably hyperbranched and hydrogenated, useful in the invention have a content of 1-6 glucosidic bonds of between 5% and 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and preferably between 15 and 20% compared to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0026] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated, useful in the invention have: - from 5% to 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15 and 20% of 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 50% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds compared to the sum of 1-2, 1-3, 1- bonds 4 and 1-6, - from 1 to 20% of 1-2 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0027] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated, useful in the invention have: - at least 5% of 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15%, - at most 70% of 1-4 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at most 60%, and most preferably at most 50%, - at least 1% of 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - at least 1% of 1-2 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

[0028] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated, useful in the invention have: - from 5% to 40%, preferably from 10 to 30%, more preferably from 12 to 22%, and most preferably from 15 to 20% of 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 70%, preferably from 42 to 60%, of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20%, preferably from 1 to 10%, more preferably from 5 to 15%, and most preferably from 5 to 10%, of 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20%, preferably from 1 to 10%, more preferably from 5 to 15%, and most preferably from 5 to 10%, of 1-2 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0029] Apart from the use of a well-known pyroconversion process applied to granular starch to prepare dextrins, i.e. by using an acid on a granular starch, typically at high temperature in a dry environment, these atypical contents of branching bonds of a starch can also be obtained by the action of a so-called "branching" or "rebranching" enzyme on a liquefied starch, such as a maltodextrin, a starch hydrolysate or a glucose syrup, possibly previously or subsequently hydrogenated.

[0030] These atypical bond contents can therefore be obtained both by the action of a so-called "branching" or "rebranching" enzyme on a liquefied starch and / or by the action of an acid, typically at high temperature in a dry environment, on a granular or liquefied starch.

[0031] The determination of the contents of 1-2, 1-3, 1-4 and 1-6 glucosidic bonds can be carried out by using the classical methylation technique described in HAKOMORI, S., 1964, J. Biochem., 55, 205. “A rapid Permethylation of Glycolipid, and Polysaccharide Catalyzed by Methylsulfinyl Carbanion in Dimethyl Sulfoxide”. This method allows the chemical characterization of glucosidic bonds by differentiating between free OH groups and bound groups. It is a destructive method comprising the steps of methylation, hydrolysis, reduction with NaBD4, acetylation and analysis by mass spectrometry.

[0032] According to one embodiment, said hyperbranched dextrins have a number-average molecular mass Mn less than or equal to 10,000 g / mol, preferably less than or equal to 4,500 g / mol, more preferably between 1,000 and 3,500 g / mol, even more preferably between 1,500 and 3,500 g / mol, and most preferably between 1,800 and 3,200 g / mol.

[0033] According to one embodiment, said hyperbranched dextrins have a polymolecularity index, ratio of the weight-average molar mass to the number-average molar mass, noted IP, less than or equal to 15, preferably less than or equal to 10, more preferably less than or equal to 5, and most preferably less than or equal to 3.

[0034] The values ​​of Mn, Mw and IP are measured by size exclusion chromatography, based on the selective retention of solute molecules according to their size, due to their penetration or not into the pores of the stationary phase. The columns The size exclusion chromatography systems used are the PSS SUPREMA 100 and the PSS SUPREMA 1000 connected in series and coupled to a light scattering detector.

[0035] According to one embodiment, said hyperbranched dextrins have a reducing sugar content of less than or equal to 20%, preferably less than or equal to 15%, more preferably less than or equal to 10%, even more preferably less than or equal to 6%, and most preferably less than or equal to 3% relative to the total mass of the hyperbranched dextrin. The reducing sugar content, expressed as glucose, by weight relative to the dry weight of the product analyzed, is determined by the BERTRAND method.

[0036] According to one embodiment, the hyperbranched dextrins useful in the invention have a relatively high residual 1-4 glucosidic bond content. This 1-4 glucosidic bond content is between 42 and 50% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, in combination with a 1-6 glucosidic bond content of between 12 and 22% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds. Preferably, the hyperbranched dextrins useful in the invention have a 1-4 / 1-6 glucosidic bond ratio of between 1.9 and 4.2 and in particular between 2.3 and 3.5.

[0037] According to one embodiment, the hyperbranched dextrins useful in the invention have a content of 1-3 glucosidic bonds of between 1 and 10% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, in combination with a content of 1-4 glucosidic bonds of between 42 and 50% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds. Preferably, the hyperbranched dextrins useful in the invention have a ratio of 1-4 / 1-3 glucosidic bonds of between 0.02 to 0.24 and in particular of between 0.1 and 0.2. According to one embodiment, the hyperbranched dextrins useful in the invention have a content of 1-2 glucosidic bonds of between 1 and 10%, in combination with a content of 1-4 glucosidic bonds of between 42 and 50%.Preferably, the hyperbranched dextrins useful in the invention have a ratio of 1-4 / 1-2 glucosidic bonds of between 0.02 and 0.24 and in particular of between 0.1 and 0.2.

[0038] According to one embodiment, the hyperbranched dextrins useful in the invention have: - from 5% to 40% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 20% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 15, - and a number-average molecular mass Mn less than or equal to 4500 g / mole.

[0039] According to one embodiment, the hyperbranched dextrins useful in the invention have: - from 10% to 30% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 70% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 10% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 10, - and a number-average molecular mass Mn between 1000 and 3500 g / mole.

[0040] According to one embodiment, the hyperbranched dextrins useful in the invention have: - from 12% to 22% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 50% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-2 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 6% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 5, - and a number-average molecular mass Mn between 1500 and 3000 g / mole.

[0041] Hyperbranched dextrins useful for the invention are commercially available, such as the products “Nutriose® FM 06”, “Nutriose® FM 10” and “Nutriose® FM15S from Roquette®, or the product range “Promitor® Soluble fiber” from Tate & Lyle.

[0042] Other commercial products available under the names “STA-LITE® Polydextrose” from Tate & Lyle, or “Oliggo-fiber®” from Cargill, are hyperbranched polysaccharides or oligosaccharides which, as such or after possible hydrogenation, could likely exhibit a soothing property like the hyperbranched dextrins according to the subject matter of the present application.

[0043] Hyperbranched and hydrogenated dextrins

[0044] According to a second embodiment, the dextrins useful for the non-therapeutic use which is the subject of the present application are hyperbranched and hydrogenated dextrins. Such dextrins can be obtained by subjecting the hyperbranched dextrins according to the subject of the present application to hydrogenation, or by applying a “branching” or “rebranching” process to a previously hydrogenated dextrin. The hydrogenation can for example be carried out by subjecting an aqueous solution of hyperbranched dextrin to gaseous hydrogen in the presence of a catalyst such as Raney nickel.

[0045] To the embodiments previously presented for hyperbranched dextrins, an additional characteristic can thus advantageously be added, namely, a reducing sugar content of less than or equal to 5% by weight, preferably less than or equal to 3% by weight, more preferably less than or equal to 2% by weight, more preferably less than or equal to 1% by weight, more preferably less than or equal to 0.5% by weight, and most preferably less than or equal to 0.15% by weight.

[0046] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the invention have: - from 5% to 40% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 4% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 15, - and a number-average molecular mass Mn less than or equal to 4500 g / mole.

[0047] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the invention have: - from 10% to 30% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 70% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 3% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 10, - and a number-average molecular mass Mn between 1000 and 3500 g / mole.

[0048] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the invention have: - from 12% to 22% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 50% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-2 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 2% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 5, - and a number-average molecular mass Mn between 1500 and 3000 g / mole.

[0049] Hyperbranched and hydrogenated dextrins useful for the invention are commercially available, such as “Nutriose® HM 06” from the Roquette company.

[0050] Soothing agent

[0051] The subject of the present invention is the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, as a soothing agent.

[0052] A soothing agent is an agent that prevents the occurrence of skin reactions and / or reactions of the oral mucous membranes or reduces the intensity of these reactions or makes them disappear.

[0053] Thus, according to one embodiment, the invention relates to the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, as a soothing agent for skin reactions and / or reactions of the oral mucous membranes.

[0054] By "cutaneous" we mean the skin, that is, the outer covering of the human body and vertebrate animals, including the human scalp. Skin reactions cause a feeling of discomfort felt in the user's skin and scalp. Skin reactions include warming, tightness, tingling, numbness, itching. These reactions are non-pathological skin reactions.

[0055] Thus, according to one embodiment, the invention relates to the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, as a soothing agent for cutaneous reactions of the skin and / or scalp.

[0056] According to one embodiment, the skin reactions are chosen from warming, tightness, tingling, numbness, itching.

[0057] The term "oral mucous membranes" refers to the lips, tongue, floor of the tongue, gums, inner surface of the cheeks and lips, palate and soft palate in humans and vertebrate animals.

[0058] Oral mucosal reactions result in a feeling of discomfort felt in the lips, gums, inner walls of the cheeks or the roof of the mouth. Oral mucosal reactions include warming, burning sensations, heating, tightness, tingling, numbness, and itching. According to one embodiment, the oral mucosal reactions are selected from burning sensations, tingling, or numbness.

[0059] These skin reactions are increased in individuals with sensitive skin or scalp. However, and unlike skin described as allergic, this reactivity is not due to an immunological process. Sensitive skin is defined by a particular reactivity. This skin reactivity is typically expressed by the manifestation of previously defined signs of discomfort such as heating, tightness, tingling, numbness, itching. These skin reactions may be in response to the subject coming into contact with a triggering element.These skin reactions can occur on all skin types but are more common on skin in a state of hypersensitivity, referred to as "sensitive skin", which corresponds to a condition of skin having increased sensitivity to external stimuli, that is to say, greater sensitivity than the average of the population, or greater than usual for an individual.

[0060] Sensitive scalp refers to scalps in which the sensations of itching and / or tingling and / or heating are mainly triggered by local factors such as friction, soap, surfactants, hard water with a high concentration of limestone, shampoos or lotions. These sensations are also sometimes triggered by factors such as the environment, emotions and / or food. Erythema and hyperseborrhea of ​​the scalp as well as a dandruff condition are frequently associated with the above signs.

[0061] According to one embodiment, the skin reactions are skin reactions of sensitive skin and scalp.

[0062] By "sensitive oral mucosa" we mean oral mucosa with an exacerbated sensitivity compared to the average sensitivity of a population, or compared to the usual sensitivity of an individual. This sensitivity can be revealed in particular by contact with surfactants such as sodium lauryl sulfate, alcohols such as ethanol, whitening agents such as peroxides or even active ingredients or essential oils, used in mouthwash, gel or toothpaste compositions.

[0063] According to one embodiment, the skin reactions and reactions of the oral mucosa are induced by endogenous or exogenous stress.

[0064] These skin reactions can be induced by exogenous stress such as - chemicals or formulation ingredients, - mechanical aggressions chosen from friction, shaving, cuts, micro-cuts, hair removal, abrasion, exfoliation, frequent washing, hard water with a high concentration of limestone, - environmental factors chosen from pollution, UV rays, sun exposure, - thermal aggressions chosen from overexposure to the sun, exposure near a source of heat or cold - foods and drinks that are abrasive or chemically aggressive to the oral mucosa,...

[0065] Skin or oral mucosal reaction can also be induced by endogenous factors such as hormonal secretions, age, stress, perspiration,

[0066] Prevention or reduction or disappearance of skin and / or oral mucosal reactions

[0067] The present invention also relates to the non-therapeutic use of hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, to prevent or reduce or eliminate skin reactions and / or reactions of the oral mucous membranes.

[0068] According to one embodiment, the skin reactions are chosen from warming, tightness, tingling, numbness, itching.

[0069] According to one embodiment, the reactions of the oral mucous membranes are chosen from sensations of burning, heating, tightness, tingling, numbness, itching.

[0070] Prevention of skin or oral mucosal reactions means preventing the occurrence of one or more skin or oral mucosal reactions, but also delaying the occurrence of one or more skin or oral mucosal reactions and preventing the worsening of one or more skin or oral mucosal reactions.

[0071] Reduction of skin or oral mucosal reactions means the reduction of one or more skin or oral mucosal reactions. For example, reduction of skin reactions means the reduction of the intensity of warming, tightness, tingling, numbness and itching. For example, reduction of oral mucosal reactions means the reduction of the intensity of warming, burning, tightness, tingling, numbness, itching and, in particular, when brushing teeth, the reduction of the intensity of dry mouth, nausea and retching.

[0072] The disappearance of skin or oral mucosal reactions means the absence of one or more skin or oral mucosal reactions.

[0073] According to one embodiment, the skin and scalp are sensitive skin and scalp.

[0074] According to one embodiment, the skin reactions and the reactions of the oral mucosa are induced by endogenous and / or exogenous stress as previously defined.

[0075] Cosmetic process

[0076] The present invention also relates to a non-therapeutic care method for the skin and / or scalp and / or oral mucosa comprising the application of hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins to the skin and / or scalp and / or oral mucosa.

[0077] Hyperbranched dextrins can be applied in the form of a cosmetic composition containing them.

[0078] According to one embodiment, the hyperbranched dextrins or the cosmetic composition comprising them is / are to be applied to the areas to be soothed of an individual presenting one or more skin reactions or oral mucous membranes and are / are optionally left in contact for several minutes or several hours and are / are optionally rinsed. This method can therefore be carried out for or after the irritation and repeat or renew as necessary, over periods ranging from a few days to several months or even several years.

[0079] Thus, according to one embodiment, the method comprises the application of hyperbranched dextrins or the cosmetic composition comprising them to the skin and / or the scalp and / or the oral mucosa exhibiting one or more skin reactions or reactions of the oral mucosa.

[0080] According to one embodiment, the method comprises an additional step in which the compound is left in contact with the skin and / or the scalp and / or the oral mucosa.

[0081] According to one embodiment, the method comprises an additional rinsing step.

[0082] Alternatively, hydrogenated hyperbranched dextrins or the cosmetic composition comprising them may be applied before the application of a cosmetic or dermatological treatment.

[0083] According to one embodiment of the invention, such a prevention method is used in cosmetic or dermatological pretreatment, in order to prevent the appearance of one or more skin reaction(s) and / or oral mucosa reaction(s) likely to occur during exposure to cold, heat, sun, a source of pollution, food, etc. or during the application of a subsequent cosmetic or dermatological treatment such as, for example, the application of a cosmetic or dermatological composition comprising one or more irritant agent(s), coloring, bleaching, permanent wave, straightening, peeling, anti-rosacea treatment, etc.

[0084] Thus, the invention also relates to a non-therapeutic care method for the skin and / or scalp and / or oral mucosa comprising at least two steps: a first pre-treatment step, intended to prevent the appearance of one or more skin reactions and / or reactions of the oral mucosa, and which comprises the application to the skin and / or scalp and / or oral mucosa of hyperbranched dextrins or the cosmetic composition comprising them, and a second step, subsequent to said first step, of application of a cosmetic or dermatological treatment.

[0085] According to one embodiment of the invention, the hyperbranched dextrins or the cosmetic composition comprising them may be applied in anticipation of endogenous and / or exogenous stress.

[0086] Endogenous and / or exogenous stress are as previously defined.

[0087] Cosmetic composition

[0088] Hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, can be incorporated into a cosmetic composition.

[0089] Thus, the present invention also relates to a cosmetic composition comprising hyperbranched dextrins and a cosmetically acceptable medium.

[0090] The term "cosmetically acceptable" means any medium that does not present harmful side effects and in particular does not produce, under normal conditions of use, redness, inflammation, heating, tightness or stinging unacceptable to a user of cosmetic products. The medium is thus compatible with the skin, scalp and oral mucous membranes of humans or animals.

[0091] According to one embodiment, the compound according to the invention may be incorporated into a cosmetic composition which contains one or more compound(s) capable of causing skin irritation.

[0092] According to one embodiment, the hyperbranched dextrins or the cosmetic composition comprising them is / are applied to non-pathological skin exhibiting one or more non-pathological skin reactions.

[0093] According to one embodiment, the content of hyperbranched dextrins is between 0.1 and 50%, preferably between 0.5 and 20%, more preferably 1 and 10% by weight, and most preferably between 1.5 and 7.5%, and generally 2 to 5% relative to the total weight of the composition.

[0094] Galenic

[0095] The cosmetic composition according to the invention may be in all the galenic forms normally used for topical application such as aqueous, hydroalcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or suspensions or emulsions, of soft, semi-solid or solid consistency, of the cream, aqueous or anhydrous gel type, anhydrous compositions, solid compositions of microemulsions, microcapsules, microparticles, or vesicular dispersions of the ionic and / or non-ionic type. For the purposes of the present invention, the term "topical application" is understood to mean in particular an application to a surface of the body, such as the skin or mucous membranes.

[0096] These compositions are prepared by the usual methods known to those skilled in the art.

[0097] This composition, when applied to the skin, can be more or less fluid and have the appearance of a cream, an emulsion or microemulsion, an ointment, a milk, a lotion, a serum, a paste, a mousse, a mask, a fluid, a balm, an oil, a gel, an ointment, a mouthwash, a toothpaste, a gum paste. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, for example in the form of a stick or patch, dry soaps, cleansing bars.

[0098] It can be used as a care product, in particular for non-rinse application, called "leave-on" in English, such as a day or night care cream for the skin of the face and / or body, as a cleaning product, as a makeup product, as a deodorant product, as a shaving product, as an aftershave product, as an after-sun product, as a sun protection product, as a lip balm protecting the lips from the cold and / or the sun and / or the wind, etc. It can also be used as a care product in rinse-off application.

[0099] The composition according to the invention may also be a composition for scalp and hair care, in particular in galenic forms for rinse-off application, known as "rinse-off" in English, such as shampoos, hair conditioners, hair masks, serums, mousses, balms, creams, sprays, conditioners, detanglers, hair creams and also in the form of a treatment lotion, a dye composition, a coloring shampoo, a perm composition, an anti-hair loss lotion or gel, an anti-parasitic shampoo, a conditioner, etc. The composition according to the invention may also be a composition for scalp and hair care, in particular in galenic forms for non-rinsed application known as "leave-on" in English.

[0100] Formulation ingredients

[0101] The cosmetic composition according to the invention may also comprise a solvent chosen according to the different ingredients and the administration form.

[0102] According to one embodiment, the composition according to the invention may comprise an aqueous phase comprising water and optionally, one or more water-miscible organic solvents.

[0103] "Water-soluble solvent" means a compound that is liquid at room temperature and miscible with water (miscibility in water greater than 50% by weight at 25°C and atmospheric pressure).

[0104] The water-soluble solvents that can be used in the compositions according to the invention can be volatile.

[0105] Among the water-soluble solvents which can be used in the compositions in accordance with the invention, mention may be made of mono-alcohols having from 1 to 5 carbon atoms such as ethanol and isopropanol, C3-C4 ketones, C2-C4 aldehydes and polyols such as in particular glycerol or glycerin, sorbitol or isosorbide.

[0106] The cosmetic composition may also include, in addition to hyperbranched dextrins:

[0107] - One or more humectants

[0108] The humectant(s) will be chosen from polyols and / or esters of fatty acids and polyethylene glycol.

[0109] The term "polyols" means any molecule having at least two free hydroxyl (-OH) groups in its structure. These polyols are preferably liquid at room temperature (25°C).

[0110] Typically, the polyol will be selected from maltitol, mannitol, xylitol, erythritol, sorbitol, isosorbide, glycerol or glycerin, glucose, sucrose, polydextrose, hydrogenated glucose syrups, dextrins, maltodextrins, glucose syrups, and mixtures thereof.

[0111] For example, we can cite the product Beauté by Roquette® PO 071 (INCI: Sorbitol), the product Beauté by Roquette® PO 260 (INCI: Mannitol), the product Beauté by Roquette® PO 370 (INCI: Xylitol), the product Beauté by Roquette® PO 455 (INCI: Hydrogenated starch hydrolysate), the product Beauté by Roquette® PO 500 (INCI: Isosorbide), all marketed by the company ROQUETTE, glycerin (INCI: glycerin) sold by the company COOPER, propylene glycol (INCI: propylene Glycol) from the company COOPER, Butylene Glycol (INCI: 1,3-BUTANEDIOL).

[0112] Among the fatty acid esters of polyethylene glycol, we can mention the product sold under the name Glucamate SSE-20 (INCI: PEG-20 METHYL GLUCOSE SESQUI STEARATE) by the company LUBRIZOL ADVANCED MATERIALS, Inc.

[0113] The composition comprises from 0.5 to 25% by weight of one or more humectants, preferably from 1 to 15% by weight, and even more preferably from 2 to 10% by weight of polyols, relative to the total weight of the composition.

[0114] - One or more oil(s)

[0115] For the purposes of the present invention, the term "oil" means a compound that is liquid at room temperature (25°C), and which, when introduced at a rate of at least 1% by weight into water at 25°C, is not at all soluble in water, or soluble to a level of less than 10% by weight, relative to the weight of oil introduced into the water. According to one embodiment, the oil will be chosen from volatile oils, non-volatile oils and mixtures thereof. Preferably, these oils are vegetable or of vegetable origin.

[0116] “Non-volatile oil” means an oil remaining on the skin, scalp or oral mucous membranes at room temperature and atmospheric pressure for at least several hours and in particular having a vapor pressure of less than 10 -3 mm of Hg (0.13Pa).

[0117] Non-volatile oils include fatty esters such as cetearyl isononoate, isotridecyl isononoate, isostearyl isostearate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, isononyl isononate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, 2-octyl decyl palmitate, 2-octyldodecyl myristate or lactate, 2-diethylhexyl succinate, diisostearyl malate, tracetin, tricprin, caprylic / capric triglycerides, coco caprate and caprylate mixture, benzoates of C12 to C15 alcohols, glycol esters such as butylene glycol cocoate, glycerin triisostearate, tocopherol acetate, higher fatty acids such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid or isostearic acid,higher fatty alcohols such as oleyl alcohol, vegetable oils such as avocado oil, camellia oil, hazelnut oil, tsubaki oil, cashew nut oil, argan oil, soybean oil, grape seed oil, sesame oil, corn oil, wheat germ oil, rapeseed oil, sunflower oil, cottonseed oil, jojoba oil, peanut oil, macadamia oil, sweet almond oil, olive oil and mixtures thereof.,

[0118] These non-volatile oils can also be hydrocarbon or silicone type oils such as paraffin oil, squalane, petrolatum, dimethyl siloxanes and their mixtures.

[0119] According to one embodiment, the non-volatile oil is chosen from stearic acid, jojoba oil (INCI: simmondsia Chinensis Seed Oil), grape seed oil (INCI: vitis vinifera seed oil), macadamia oil (INCI: Macadamia ternifolia seed oil), refined oleic sunflower oil (Helianthus annuus seed oil), the mixture of coconut caprate and caprylate such as the product Miglyol Coco 810 (INCI: Coco-Caprylate / Caprate), sweet almond oil (INCI: Prunus Amygdalus Dulcis Oil), sesame oil (INCI: Sesamum indicum seed oil).

[0120] Volatile oil is defined as an oil that can evaporate from the skin in less than an hour at room temperature and atmospheric pressure. Volatile oils can be chosen, for example, from silicone oils or short fatty acid triglycerides to reduce the greasy feel.

[0121] According to one embodiment, the oil(s) is / are present in a content ranging from 0.5 to 70% by weight, preferably from 1 to 60% by weight, preferably from 2 to 50% by weight, preferably from 5 to 40% by weight, preferably from 5 to 30% by weight relative to the total weight of the composition.

[0122] - One or more wax(es) and / or one or more pasty compound(s).

[0123] The term "wax" means a fatty substance with a reversible liquid / solid state change, having a melting point above 25°C, generally between 30°C and 90°C, which can be made liquid under the conditions of preparation of the composition and has an anisotropic crystalline organization in the solid state. The waxes used according to the invention may consist of polar or apolar waxes or a mixture of the two. The term "apolar" means a wax containing only carbon, hydrogen and / or phosphorus atoms and in particular a hydrocarbon.

[0124] Polar waxes may in particular be chosen from animal waxes, vegetable waxes and synthetic or silicone waxes containing polar groups such as esters. Mention may thus be made of Carnauba wax, Candelilla wax, beeswax (Cera alba), Chinese insect wax (Ericerus pela), Japanese wax, Sumac wax, Montan wax, C8-C20 acid triesters and glycerin such as glycerin tribehenate, acetylated glycol stearate marketed in particular by the company VEVY under the trade name CET ACENE, and mixtures thereof. These waxes may in particular be used in pre-dispersed form in an oil, as is the case with the mixture of candelilla wax and jojoba seed oil.

[0125] According to one embodiment, the wax or waxes is / are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition. Preferably, these waxes are vegetable or of vegetable origin.

[0126] “Pasty compound” means lipophilic fatty substances which, like waxes, are capable of undergoing a reversible liquid / solid state change and have an anisotropic crystalline organization in the solid state, but which differ from waxes in that they contain, at a temperature of 23°C, a liquid fraction and a solid fraction.

[0127] According to one embodiment, the pasty compound(s) is / are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition. These pasty compounds are preferably vegetable butters or butters of vegetable origin, such as shea butter or camellia butter.

[0128] According to one embodiment, the pasty compound(s) is / are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition.

[0129] - One or more qualifying agent(s)

[0130] A gelling agent is a compound which, in the presence of a solvent, creates more or less strong inter-macromolecular bonds, thus inducing a three-dimensional network which freezes the said solvent. A gelling agent is also a thickening or rheological agent, acting on the viscosity and flow properties of an aqueous phase or a fatty phase.

[0131] The gelling agent makes it possible in particular to increase the viscosity of the continuous phase, i.e. to adjust the viscosity of the continuous phase to a value ranging from 100 mPa.s to 20,000 mPa.s.

[0132] The gelling agent may be chosen from polymers of synthetic or plant origin, preferably of plant origin, chemically modified or not.It can thus be chosen from gums derived from plants such as gum arabic, konjac gum, guar gum or their derivatives, gums extracted from algae such as alginates; gums derived from microbial fermentation such as xanthans, for example, the product Keltrol CG (INCI: xanthan gum), sold by the company CP KELCO or the product Xanthan Gum FNCS-PC (INCI: xanthan gum) sold by the company JUNGBUNZLAUER INTERNATIONAL AG, mannans, scleroglucans or their derivatives; cellulose and its derivatives such as carboxymethylcellulose or hydroxyethylcellulose; starch and its derivatives such as in particular native starches and modified starches, in particular pregelatinized, acetylated, hydroxypropylated, carboxymethylated, cationic, octenylsuccinate, crosslinked, possibly several times modified starches; synthetic polymers such as polyacrylic acids or carbomers, and their mixtures.

[0133] Starches and starch-based mixtures include Beauté by Roquette® ST 118 (INCI: Carboxymethyl starch), Beauté by Roquette® ST 720 (INCI: Hydroxypropyl starch) and Beauté by Roquette® DS112 (INCI: Starch acetate (and) Hydroxyethylcellulose (and) Xanthan gum), all sold by the company ROQUETTE.

[0134] Examples of carbomers include the product Carbopol Ultrez 30 (INCI: carbomer) from LUBRIZOL ADVANCED MATERIALS, Inc. or CARBOPOL ETD 2050 POLYMER (INCI: carbomer).

[0135] We will also mention mixtures of gum arabic and xanthan gum such as the product Solagum AX (INCI: Acacia Senegal Gum (and) Xanthan Gum), sold by the company SEPPIC, mixtures of starch and cellulose derivatives such as the product Beauté by Roquette® DS112 (INCI: Starch acetate (and) Hydroxyethylcellulose (and) Xanthan gum), sold by the company ROQUETTE.

[0136] The gelling agent may be a mineral gelling agent selected from magnesium and / or aluminum silicates. An example of such a mineral gelling agent is Veegum® Pure from Vanderbilt Minerals LLC, which is a magnesium aluminum silicate.

[0137] According to one embodiment, the gelling agent(s) is / are present in a content ranging from 0.1 to 50% by weight, preferably from 0.5 to 25% by weight, preferably from 0.3 to 15% by weight, relative to the total weight of the composition.

[0138] - One or more binders

[0139] The term "binder" refers to compounds that provide increased cohesion to the cosmetic composition. This cohesion can be adjusted depending on the quantity and chemical affinity of the binding agent in relation to the ingredients of the cosmetic composition.

[0140] Typically, the binder will be chosen from caprylic / capric acid triglycerides such as the product Labrafac CC (INCI: capric / caprylic triglicerides) or Cetyl Dimethicone (INCI).

[0141] The binder(s) is / are present in the composition according to the invention at a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 5 to 12%, by weight relative to the total weight of the composition.

[0142] - One or more emulsifying agent(s)

[0143] The cosmetic composition according to the invention may also comprise one or more oil-in-water (O / W) or water-in-oil (W / O) emulsifiers.

[0144] The oil-in-water (O / W) emulsifier is an emulsifying agent with an HLB greater than or equal to 8 and chosen from optionally polyethoxylated sorbitan esters, fatty acid esters of glycerol, fatty acid esters or polyesters of sucrose, fatty acid esters of polyethylene glycol, modified polysiloxanes polyethers, ethers of fatty alcohols and polyethylene glycol, alkylpolyglycosides and hydrogenated lecithin, fatty alcohols, sorbitan esters without this list being exhaustive, and mixtures thereof.

[0145] Examples include, for example, the product Montanov 68 (INCI: CETEARYL ALCOHOL (AND) CETEARYL GLUCOSIDE), marketed by the company SEPPIC, the product Montanov L (INCI: C14-C22 Alcohols & C12-20 Alkyl Glucoside), marketed by the company SEPPIC, Montanov 202 (INCI: Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside), Citrol GMS 40 (INCI: Glyceryl stearate), sold by the company CRODA, or the product Imwitor 960K (INCI: Glyceryl stearate), sold by the company BIESTERFELD, the product Imwitor 372P (INCI: Glyceryl stearate citrate), sold by the company BIESTERFELD, the product Glucate SS (INCI: Methyl Glucose Sesquistearate), sold by the company LUBRIZOL ADVANCED MATERIALS, Inc, the stearic plural (Polyglyceryl-6 Distearate), Natragem E145 (INCI: Polyglyceryl-4 Laurate / Succinate (and) Aqua), sold by the company CRODA, the product Span 60 (INCI: sorbitan stearate), sold by the company SIGMA ALDRICH.

[0146] Among the sorbitan esters, we can cite, for example, the product Span 20.

[0147] Among the fatty alcohols, we can cite for example the product sold under the name Promulgen D (INCI: Cetearyl alcohol (and) Ceteareth-20).

[0148] The H / W emulsifier can advantageously be chosen from emulsifying systems composed of a cyclodextrin and a water-in-oil emulsifier of natural origin, such as the emulsifying system marketed by Roquette Frères under the name Beauté by Roquette® DS 146.

[0149] The H / W emulsifier can also be chosen from emulsifying systems composed of modified starches and natural gums such as the emulsifying system marketed by Roquette Frères under the name Beauté by Roquette® DS 421.

[0150] The water-in-oil (W / O) emulsifier is an emulsifying agent with an HLB of less than 8 and chosen from non-ethoxylated fatty esters of polyols, and in particular from non-ethoxylated fatty esters of glycerol, polyglycerols, sorbitol, sorbitan, anhydrodrohexitols such as in particular isosorbide, mannitol, xylitol, erythritol, maltitol, sucrose, glucose, polydextrose, hydrogenated glucose syrups, dextrins and hydrolyzed starches.

[0151] The emulsifying agent(s) is / are present in the composition according to the invention at a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 2 to 12%, by weight relative to the total weight of the composition.

[0152] - One or more surfactants

[0153] According to one embodiment, the composition according to the invention comprises at least one surfactant chosen from ionic, non-ionic, cationic, anionic or amphoteric or zwitterionic surfactants. These surfactants are chosen for their detergent and foaming function.

[0154] According to another embodiment, the composition according to the invention comprises at least one surfactant chosen from anionic surfactants, amphoteric or zwitterionic surfactants.

[0155] The anionic surfactants are chosen from carboxylic anionic surfactants, sulfated anionic surfactants, sulfonate surfactants, phosphate anionic surfactants, and mixtures thereof, preferably from sulfonate anionic surfactants, carboxylic anionic surfactants, and mixtures thereof.

[0156] By "anionic surfactant" is meant a surfactant comprising only anionic groups as ionic or ionizable groups. In the present description, an entity is described as being "anionic" when it has at least one permanent negative charge or when it can be ionized into a negatively charged entity, under the conditions of use of the composition of the invention (medium, pH for example) and not comprising a cationic charge. By "sulfated anionic surfactant" is meant an anionic surfactant comprising at least one sulfate function (- OSO3H or -OSO3), and which may optionally also comprise one or more other functions derived from acids, such as carboxylic acid or carboxylate functions (-COOH or -COO), sulfonate functions (-SO3H or -SO3) and / or phosphate functions.For example, alkyl sulfates, alkyl ether sulfates, alkylamido ether sulfates, alkylaryl polyether sulfates, monoglyceride sulfates, and the salts of these compounds are sulfated anionic surfactants. The alkyl groups of these exemplary compounds contain from 6 to 30 carbon atoms, and the aryl group denotes a phenyl or benzyl group. These exemplary compounds may be polyoxyalkylenated, in particular polyoxyethylenated, and contain from 1 to 50 ethylene oxide units. The term "non-sulfated anionic surfactant" means a surfactant that does not fall within the definition of "sulfated anionic surfactant" as defined above.

[0157] It is also understood according to the invention that: - carboxylic anionic surfactants comprise at least one carboxylic or carboxylate function (-COOH or -COO), but do not comprise a sulfonic or sulfonate function (-SO3H or -SO3), nor a sulfate function (-OSO3H or -OSO3); - the anionic sulfonate surfactants comprise at least one sulfonic or sulfonate function (-SO3H or -SO3), and may optionally also comprise one or more carboxylic or carboxylate functions (-COOH or -COO) and / or phosphates, but do not comprise a sulfate function (-OSO3H or -OSO3). - phosphate anionic surfactants comprise at least one phosphoric or phosphate function (-OPO3H2 or -OPO3 2 ), but do not include a carboxylic or carboxylate function (-COOH or -COO), nor a sulfonic or sulfonate function (-SO3H or -SO3), nor a sulfate function (-OSO3H or -OSO3).

[0158] In other words: - an anionic surfactant comprising at least one sulfate function (-OSO3H or -OSO3), and at least one carboxylic or carboxylate function (-COOH or -COO), is considered, within the meaning of the invention and unless otherwise indicated, as a sulfated anionic surfactant; - an anionic surfactant comprising at least one sulfate function (-OSO3H or -OSO3), and at least one sulfonic or sulfonate function (-SO3H or -SO3), is considered, within the meaning of the invention and unless otherwise indicated, as a sulfated anionic surfactant; - an anionic surfactant comprising at least one sulfonic or sulfonate function (- SO3H or -SO3), and at least one carboxylic or carboxylate function (-COOH or -COO), is considered, within the meaning of the invention and unless otherwise indicated, as a non-sulfated sulfonate anionic surfactant; • an anionic surfactant comprising at least one sulfate function (-OSO3H or -OSO3), and at least one sulfonic or sulfonate function (- SO3H or -SO3), and at least one carboxylic or carboxylate function (-COOH or -COO), is considered, within the meaning of the invention and unless otherwise indicated, as a sulfated anionic surfactant.

[0159] The carboxylic anionic surfactants may be chosen from the following compounds: acylglycinates, acyllactylates, acylsarcosinates, acylglutamates; alkyl-D-galactoside-uronic acids, alkyl ether carboxylic acids, alkyl(aryl) ether carboxylic acids, alkylamido ether carboxylic acids; as well as the salts of these compounds. The alkyl and / or acyl groups of these compounds contain from 6 to 30 carbon atoms, more preferably from 8 to 28, even more preferably from 10 to 24, even better still from 12 to 22, carbon atoms. The aryl group preferably denotes a phenyl or benzyl group. These compounds may be polyoxyalkylenated, in particular polyoxyethylenated, and then preferably comprise from 1 to 50 ethylene oxide units, better still from 2 to 10 ethylene oxide units.Also useful are C6-C24 alkyl monoesters of polyglycoside-polycarboxylic acids such as C6-C24 alkyl polyglycosidecitrates, C6-C24 alkyl polyglycoside tartrates, and their salts.

[0160] According to one embodiment, the carboxylic anionic surfactants are chosen from: - acylglutamates, in particular C6-024, or even C12-020, such as stearoylglutamates, and in particular sodium or disodium stearoylglutamate or cocoylglutamates, in particular sodium or disodium cocoyl glutamate; - acylsarcosinates, particularly C6-024, or even C12-020, such as cocoyl sarcosinates and in particular sodium cocoyl sarcosinate, lauroyl sarcosinates and in particular sodium lauroyl sarcosinate, palmitoylsarcosinates, and in particular sodium palmitoylsarcosinate; - acyllactylates, in particular 012-028, or even 014-024, such as behenoyllactylates, and in particular sodium behenoyllactylate, (iso)stearoyl lactylates, and in particular sodium (iso)stearoyl lactylated; - C6-024 acylglycinates, in particular C12-020 such as cocoyl glycinates and in particular sodium cocoyl glycinate; - alkyl(C6-C30)ethercarboxylic acids, in particular alkyl(C6-C24)ethercarboxylic acids; - alkyl(C6-C30) aryl ethercarboxylic acids, in particular alkyl(C6-C24) aryl ethercarboxylic acids; - alkyl(C6-C30)amidoethercarboxylic acids, in particular alkyl(C6-C24)amidoethercarboxylic acids; - and their mixtures; and in particular in the form of salts of alkali or alkaline-earth metals, ammonium, or amino alcohol.

[0161] The anionic sulfonate surfactants may be chosen from the following compounds: alkylsulfonates, alkylamidesulfonates, alkylarylsulfonates, C6-C24 alkyl polyglycoside sulfosuccinates, alpha-olefinsulfonates, paraffinsulfonates, alkylsulfosuccinates, alkylethersulfosuccinates, alkylamidesulfosuccinates, alkylsulfoacetates, N-acyltaurates, acylisethionates; alkylsulfolaurates; as well as the salts of these compounds; the alkyl groups of these compounds comprising from 6 to 30 carbon atoms, in particular from 12 to 28, even better from 14 to 24, or even from 16 to 22, carbon atoms; the aryl group preferably denoting a phenyl or benzyl group; these compounds may be polyoxyalkylenated, in particular polyoxyethylenated and then preferably comprising from 1 to 50 ethylene oxide units, better still from 2 to 10 ethylene oxide units.

[0162] According to one embodiment, the anionic sulfonate surfactants are chosen from: C6-C24 alkylsulfosuccinates, in particular C12-C20, in particular laurylsulfosuccinates; C6-C24 alkylethersulfosuccinates, in particular C12-C20; (C6-C24) acylisethionates, preferably (C12-C18) acylisethionates; alpha-olefin sulfonates; and mixtures thereof; and in particular in the form of alkali or alkaline-earth metal, ammonium, or amino alcohol salts.

[0163] According to one embodiment, the anionic surfactants may be chosen from C6-C24 alkyl monoesters of polyglycoside dicarboxylic acids such as alkyl glucoside citrates, alkyl polyglycoside tartrates and alkyl polyglycoside sulfosuccinates, alkyl sulfosuccinamates, acylisethionates and N-acyltaurates, the alkyl or acyl group of all these compounds preferably comprising from 12 to 20 carbon atoms. Another group of anionic surfactants usable in the compositions of the present invention is that of acyllactylates whose acyl group comprises from 8 to 20 carbon atoms.In addition, mention may also be made of alkyl-D-galactosideuronic acids and their salts as well as polyoxyalkylenated (C6-C24 alkyl)ethercarboxylic acids, polyoxyalkylenated (C6-24 alkyl)(C6-C24 aryl)ethercarboxylic acids, polyoxyalkylenated (C6-24 alkyl)amidoethercarboxylic acids and their salts, in particular those comprising from 2 to 50 ethylene oxide units, and mixtures thereof.

[0164] The anionic phosphate surfactants are chosen from: alkyl phosphates in 06-024, in particular in 012-020; alkyl ether phosphates in 06-024, in particular in 012-020; and mixtures thereof.

[0165] The amphoteric or zwitterionic surfactants may be chosen from derivatives of secondary or tertiary or quaternary aliphatic amines, in which the aliphatic group is a linear or branched chain comprising from 8 to 22 carbon atoms and containing at least one anionic group such as, for example, a carboxylate, sulfonate, sulfate, phosphate or phosphonate group. Mention may also be made of: alkyl(C8-C20)betaines, for example cocobetaine; sulfobetaines; alkyl(C8-C20)sulfobetaines; alkyl(C8-C20)amidoalkyl(C3-C8)betaines, for example cocamidopropylbetaine; or alkyl(C8-C20)amidoalkyl(C6-C8)sulfobetaines.

[0166] Cationic surfactants can be chosen from Cetrimonium Chloride marketed under the reference Microcare Quat CTC 30.

[0167] The surfactant(s) is / are present in the composition according to the invention at a content ranging from 0.1% to 40%, preferably from 0.5 to 30%, preferably from 1 to 20%, preferably from 2 to 12% by weight relative to the total weight of the composition.

[0168] - One or more film-forming agent(s)

[0169] The film-forming agent may be chosen from polymers of natural origin such as hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), or synthetic polymers such as polyvinyl alcohol (PVA), and / or plasticizers other than polyols, such as polyethylene glycol, triethyl citrate, polysorbate, or waxes such as carnauba wax, or hydrogenated castor oil.

[0170] Another film-forming agent of plant origin is hydroxypropylated pea starch Beauté by Roquette® ST 720, sold by the company ROQUETTE.

[0171] The film-forming agent(s) is / are present in the composition according to the invention at a content ranging from 0.1% to 20%, preferably from 0.5 to 15%, preferably from 1 to 12%, by weight relative to the total weight of the composition.

[0172] One or more coloring matter(s)

[0173] The cosmetic composition according to the invention may also comprise at least one coloring matter chosen from water-soluble or fat-soluble colorants, fillers having the effect of coloring and / or opacifying the composition and / or coloring the skin or hair or oral mucous membranes, such as pigments, pearlescent agents, lakes (water-soluble colorants adsorbed on an inert mineral support), and mixtures thereof. These coloring matters may optionally be surface-treated with a hydrophobic agent such as silanes, silicones, fatty acid soaps, C9-15 fluoroalcohol phosphates, acrylate / dimethicone copolymers, mixed C9-15 fluoroalcohol phosphate / silicone copolymers, lecithins, carnauba wax, polyethylene, chitosan and optionally acylated amino acids such as lauroyl lysine, disodium stearoyl glutamate and aluminum acyl glutamate, phytic acid.Another natural colorant is Beauté by Roquette® CC 001 caramel colorant, sold by the company ROQUETTE.

[0174] “Pigments” are white or colored particles, mineral or organic, intended to color and / or opacify the cosmetic composition.

[0175] Pigments include mineral or organic pigments, whether natural or synthetic. Examples of pigments include iron, titanium or zinc oxides, as well as composite pigments and goniochromatic, pearlescent, interference, photochromic or thermochromic pigments, but this list is not exhaustive.

[0176] Among the pigments surface-treated with lecithins, we can mention the products UNIPURE WHITE LC981 HLC (INCI: Cl 77891 (and) Hydrogenated Lecithin, UNIPURE YELLOW LC182 HLC (INCI: Cl 77492 (and) Hydrogenated Lecithin), UNIPURE BLACK LC989 HLC (INCI: Cl 77499 (and) Hydrogenated Lecithin, UNIPURE RED LC381 HLC (INCI: Cl 77491 (and) Hydrogenated Lecithin) from the company Sensient Cosmetic Technologies.

[0177] Among the pigments treated on the surface with phytic acid, we will cite the products Unipure White LC 985 PHY (INCI: Cl 77891 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Yellow LC 188 PHY (INCI: Cl 77492 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Red LC 388 PHY (INCI: Cl 77491 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Black LC 998 PHY (INCI: Cl 77499 (and) Phytic Acid (and) Sodium Hydroxide), from the company Sensient Cosmetic Technologies.

[0178] The term “mother-of-pearl” refers to any colored particles, iridescent or not, which present a color effect through optical interference.

[0179] Among the nacres, we can cite titanium mica covered with metallic oxide such as iron oxide or titanium oxide.

[0180] According to one embodiment, the makeup and / or care composition according to the invention comprises at least colored particles, preferably pigments such as iron oxide pigments and / or mother-of-pearl.

[0181] The coloring matter(s) is / are present in the composition according to the invention at a content ranging from 0.05% to 20%, preferably from 0.1% to 15%, preferably from 0.5 to 12%, by weight relative to the total weight of the composition.

[0182] - One or more sensory fillers or powders

[0183] This term means any particle of any shape (in particular spherical or lamellar), mineral or organic, insoluble in the composition. Examples of sensory fillers or powders are talc, boron nitride, starch such as the granular starches Beauté by Roquette® ST 005 and Beauté by Roquette® ST 012 sold by the company ROQUETTE, polyamides, silicone resins, silicone elastomer powders and acrylic polymer powders, in particular poly(methyl methacrylate) or styrene acrylate copolymer powders (Sunsphere Powders from Dow).

[0184] The filler(s) is / are present in the composition according to the invention at a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 3 to 12%, by weight relative to the total weight of the composition.

[0185] One or more sensory agent(s)

[0186] Sensory agents allow the sensory profile of the cosmetic or dermatological composition to be modified, to make it more pleasant to use on the skin. Sensory agents can be chosen from modified starches such as carboxymethyl starches, for example Beauté by Roquette ST 118 from Roquette, silicas, or talcs, or mixtures thereof. These sensory agents provide softness to the touch for solid compositions, or a cushion effect for compositions in liquid or gel form.

[0187] The sensory agent(s) is / are present in the composition according to the invention at a content ranging from 0.1% to 20%, preferably from 1 to 15%, preferably from 3 to 12%, by weight relative to the total weight of the composition.

[0188] - One or more active ingredient(s)

[0189] In addition to hyperbranched dextrins, the cosmetic composition may include one or more active ingredients.

[0190] These active ingredients may be of a very broad chemical nature due to the fact, as the applicant has been able to observe, that hyperbranched dextrin, preferably hyperbranched and hydrogenated dextrin, is rather inert, has low reactivity and very good compatibility with most of the active ingredients used in cosmetic or even dermatological compositions. These active ingredients may be chosen from moisturizing, emollient, film-forming, barrier, anti-pollution, tensor, anti-aging, anti-oxidant, exfoliating, collagen stimulating, anti-acne, sebum reducing, blood circulation stimulating, refreshing, antibacterial, antifungal, anti-inflammatory, soothing, anti-irritant, healing, slimming, pigmenting, coloring, mattifying and perfuming agents.

[0191] Among the soothing agents, those extracted from plants will be preferentially used. Mention will be made, as a soothing agent and by way of illustration, of C-glycosides such as those described in document FR2902998. Mention will also be made, in particular, as soothing agents, of natural products such as ceramides, sweet almond or chamomile oils, extracts of mimosa tenuiflora (tepescohuite), aloe vera, licorice (glycorhetinic acid), calendula, St. John's wort, oats, linden, magnolia, marshmallow or mallow.

[0192] Preferably, hyperbranched dextrins, preferably hyperbranched and hydrogenated, can be combined with an anti-inflammatory cosmetic active ingredient or another soothing active ingredient.

[0193] The active ingredient(s) is / are present in the composition according to the invention at a content ranging from 0.05% to 20%, preferably from 0.1 to 10%, preferably from 0.5 to 6%, by weight relative to the total weight of the composition. Examples

[0194] Example 1: Clinical study on the sensations of discomfort induced by sodium lauryl sulfate

[0195] The objective of the study was to determine the effect of a hyperbranched and hydrogenated dextrin, sold under the reference Nutriose® HM 06 by Roquette, on the sensations of discomfort created by exposure of the skin of the inner forearm of volunteers to a product aggressive to the skin, namely sodium lauryl sulfate (SLS), applied by a patch at a concentration in water of 10%.

[0196] Volunteers and products

[0197] This non-invasive, single-center study was conducted on forty male volunteers aged between 30 and 55 years old, with sensitive skin (based on their self-report). The inclusion criteria for the volunteers are presented in the table.

[0198] [Table 1]

[0199] The volunteers were divided into two homogeneous groups of 20 volunteers, and each group received a lotion according to the table below.

[0200] Composition of lotions

[0201] [Table 2]

[0202] Study protocol

[0203] At the start of the study (day 0), 10% SLS patches were placed on the two demarcated areas on the forearms of each volunteer. The volunteers kept the patches on for 20 hours, and removed them 4 hours before the self-assessment on day 1, so that on day 1, self-assessments were made on both forearms of all volunteers. Immediately after the measurement on day 1, each group applied their lotion to the area exposed to the SLS patch on the right forearm, this is the treated area, then a self-assessment was made 5, 10 and 30 minutes after this application. The left forearm received no treatment with lotion, this is the untreated area.

[0204] From day 1 to day 6, volunteers applied the same lotion to the SLS-exposed area of ​​the right forearm every evening. The left forearm received no treatment. On days 2, 3, 4, and 7, self-assessments of the lotion-treated area and the untreated area were made.

[0205] Self-assessment

[0206] The volunteers self-rated the sensations of discomfort of heating and tightness for the treated area and for the untreated area, on semi-structured scales, ranging from 1 to 10, 1 corresponding to a “not intense” sensation and 10 corresponding to a “very intense” sensation.

[0207] Results

[0208] [Table 3]

[0209] The table describes the average values ​​of self-assessment of the feeling of warming.

[0210] [Table 4] ;0211] The table describes the mean values ​​of self-assessment of the feeling of tightness.

[0212] To compare the changes in the sensations of heating and tightness between the different groups, we calculated the variations in these sensations between the different measurement times, for example for a treated area of ​​skin:

[0213] [Math.1] ΔTreated((Day x) - Day 1) = (sensation assessed in the treated area on day x) - (sensation assessed in the treated area on day 1), for both groups.

[0214] [Table 5]

[0215] The table describes the average variations in the sensations of heating and tightness over time between the treated and untreated skin areas.

[0216] Nutriose® HM 06 hyperbranched dextrin reduces the sensations of heating caused by SLS from 10 minutes compared to the placebo group, and this reduction is increased and maintained thereafter for up to 7 days.

[0217] Nutriose® HM 06 hyperbranched dextrin reduces the sensations of tightness caused by SLS from 5 minutes compared to the placebo group, and this reduction is maintained on average for up to 4 days.

[0218] The reduction of the sensations of heating and tightness of the skin by application of Nutriose® HM 06 hyperbranched dextrin has shown that this dextrin has helped to soothe skin reactions caused by the 10% SLS patch. Nutriose® HM 06 hyperbranched and hydrogenated dextrin is therefore soothing.

[0219] Example 2: Cosmetic product formulations comprising a hyperbranched and hydrogenated dextrin according to the subject of the application

[0220] Roquette's Nutriose® HM 06 hyperbranched and hydrogenated dextrin, due to its particular chemical nature described above, presents, as the applicant has been able to observe, very low or no reactivity with most of the active ingredients used in cosmetic and dermatological compositions and therefore very good compatibility and ease of use for the formulator.

[0221] In fact, it can act as a calming effect in a large number of formulations, such as those which follow and which are given for illustrative and non-limiting purposes.

[0222] After-sun cream

[0223] [Table 6]

[0224] Preparation protocol: Phase A and phase B were prepared at 70°C in two separate beakers. Phase B was then emulsified in phase A under high shear stirring for 10 minutes. The mixture was then cooled to 20°C + / -2°C. Phase C was then added under stirring, followed by phase D. The pH was finally adjusted to 6. A white cream was obtained with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle no. 4 at 20 rpm).

[0225] Aftershave gel

[0226] [Table 7] ;0227] Preparation protocol: isosorbide and Nutriose were previously mixed HMC 06 in the quantity of water required for phase A, then the Beauté by Roquette DS 112 starch was dispersed in it at 80°C for 30 to 40 minutes. Phases B1 and B2 were then added successively, and the pH was adjusted to 6. A translucent gel was obtained, with a Brookfield viscosity of 3500 mPa. s + / -700 (spindle no. 4 at 20 rpm).

[0228] Soothing oil-in-water emulsion

[0229] [Table 8]

[0230] Preparation protocol: Nutriose HMC 06 was added to half the volume of water required for the formulation at 45°C while stirring with a deflocculator at 500 rpm until a clear solution was obtained. Separately, the ingredients of phase A2 were mixed in half the volume of water required for the formulation while stirring at 500-1000 rpm. Phase A1 and phase A2 were then mixed, and then phase A3 was added while stirring at 1500 rpm for 10 minutes. Separately, phase B was prepared by heating it to 45°C. Then, phase B was emulsified in phase A1+A2+A3 while stirring vigorously at 2000-3000 rpm for 15 minutes at 45°C. The mixture was cooled to 20°C + / -2°C, then phases C, D, E and F were successively added while stirring at 500 rpm, and the pH was adjusted to 5.3 + / -0.2. This gave a blue emulsion with a Brookfield viscosity of 4500-5500 mPa. s (spindle no. 3 at 20 rpm).

[0231] Soothing and restorative hand cream

[0232] [Table 9]

[0233] Preparation protocol: Nutriose HMC 06 was added to the volume of water required for the formulation at 45°C while stirring with a deflocculator at 500 rpm until a clear solution was obtained, then cooled to 20°C + / -2°C. Beauté by Roquette DS 421 was then dispersed in phase A while stirring with a deflocculator at 1000 rpm for approximately 10 minutes so that this ingredient was hydrated, which was visually observed by its opalescence. Separately, phase C was prepared. At room temperature (20°C + / - 2°C), phase C was added to phase A + B slowly and with stirring using a deflocculator at 2000-3000 rpm, then stirring was continued for 10 minutes. Finally, phase D was added with stirring at 1000-2000 rpm, then adjusted to pH 4.5-4.7. A yellow cream was obtained, with a Brookfield viscosity of 8800 mPa. s (spindle 3 at 20 rpm).

[0234] Soothing Cleansing Cream (TQ-027-001)

[0235] [Table 10]

[0236] Soothing Hair Conditioning Gel (HC-040-001)

[0237] [Table 11] j0238] Soothing Conditioning Cream for Hair (HC-040-002)

[0239] [Table 12]

[0240] Soothing Elixir (SC-073-003)

[0241] [Table 13]

[0242] Shampoo without sulfate surfactant (HC-031-002)

[0243] [Table 14]

[0244] Soothing Shampoo (HC-025-008)

[0245] [Table 15]

[0246] After-sun cream (SC-073-011)

[0247] [Table 16]

[0248] Preparation protocol: Disperse Nutriose HM® 06 in the mixture of water and Beauté by Roquette® PO 070 sorbitol with gentle stirring. Then add Beauté by Roquette® DS 112, and heat to 80°C with stirring using a deflocculating paddle at medium speed, and maintain at this temperature with stirring for 40 minutes to obtain a homogeneous gel. Then let cool to 25-30°C with gentle stirring. Then add phase B with medium stirring, and maintain stirring for 5 minutes. Then add phase C with medium stirring, then phase D with medium stirring, and maintain stirring for 5 minutes. Add phase E with gentle stirring. Finally, adjust the pH to 5 with phase F. [02491 Solar Barrier Stick (SU-024-018))

[0250] [Table 17] ;0251] Preparation protocol: the ingredients of phase A are mixed with stirring while heating to 80°C. Separately, phase B is prepared with vigorous stirring using a deflocculating blade (2000 rpm) until all the ingredients are well dispersed. Phase A is cooled to 60°C, then added to phase B with gentle stirring. Maintaining at 60°C, the mixture is poured into a mold and then allowed to cool to 20°C. A solid composition is obtained in the form of a stick.

Claims

Demands

1. Non-therapeutic use of hyperbranched dextrins, preferably of hyperbranched and hydrogenated dextrins, as a soothing agent, characterized in that said dextrins comprise at least 5% of 1-6 glycosidic linkages relative to the sum of 1-2, 1-3, 1-4 and 1-6 linkages.

2. Non-therapeutic use according to claim 1, characterized in that said dextrins have: - from 5% to 40% of 1-6 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 42 to 50% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-3 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-2 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

3. Non-therapeutic use according to claim 1, characterized in that said dextrins have: - at least 5% of 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% - at most 70% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at most 60%, and most preferably at most 50%, - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% - at least 1% of 1-2 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

4. Non-therapeutic use according to any one of claims 1 to 3, characterized in that the soothing agent is a soothing agent for skin reactions and / or oral mucosal reactions.

5. Non-therapeutic use of hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, to prevent, reduce, or eliminate skin and / or oral mucosal reactions, characterized in that said dextrins comprise at least 5% of 1-6 glycosidic linkages relative to the sum of 1-2, 1-3, 1-4 and 1-6 linkages.

6. Non-therapeutic use according to claim 5, characterized in that said dextrins have: - from 5% to 40% of 1-6 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 42 to 50% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-3 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-2 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

7. Non-therapeutic use according to claim 5, characterized in that said dextrins have: - at least 5% of 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% - at most 70% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at most 60%, and most preferably at most 50%, - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% - at least 1% of 1-2 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

8. Non-therapeutic use according to any one of claims 1 to 7, characterized in that the skin reactions are skin reactions of the skin and / or scalp and are selected from the following: burning, pulling, tingling, numbness, itching.

9. Non-therapeutic use according to any one of claims 1 to 7, characterized in that the reactions of the oral mucosa are selected from burning sensations, heating, pulling, tingling, numbness, itching.

10. Non-therapeutic use according to any one of claims 1 to 9, characterized in that the skin and / or scalp and / or oral mucosa are sensitive.

11. Non-therapeutic use according to any one of claims 1 to 10, characterized in that the skin reactions and / or oral mucosal reactions are induced by endogenous and / or exogenous stress.

12. Non-therapeutic use according to any one of claims 1 to 1 1, characterized in that the exogenous stress is selected from chemicals or formulation ingredients, mechanical stresses, environmental factors, thermal stresses, food and beverages.

13. Non-therapeutic use according to any one of claims 1 to 12, characterized in that the endogenous stress is selected from hormonal secretions, age, stress, perspiration.

14. A non-therapeutic soothing treatment method for the skin and / or scalp and / or oral mucosa comprising the application of hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, to the skin and / or scalp and / or oral mucosa, characterized in that said dextrins comprise at least 5% of 1-6 glycosidic linkages relative to the sum of 1-2, 1-3, 1-4 and 1-6 linkages.

15. A non-therapeutic treatment method according to claim 14, characterized in that said dextrins have: - from 5% to 40% of 1-6 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 42 to 50% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-3 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-2 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

16. Non-therapeutic treatment method according to claim 14 or 15 comprising the application of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, to the skin and / or scalp and / or oral mucosa exhibiting one or more skin reactions.

17. A non-therapeutic treatment method according to claim 14 or 15 characterized in that hyperbranched dextrins, preferably dextrins hyperbranched and hydrogenated, are applied to the skin and / or scalp and / or oral mucous membranes in anticipation of the application of a cosmetic or dermatological treatment or of endogenous and / or exogenous stress.

18. Cosmetic composition comprising, in a cosmetically acceptable medium, hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, characterized in that said dextrins comprise at least 5% of 1-6 glycosidic linkages relative to the sum of 1-2, 1-3, 1-4 and 1-6 linkages.

19. Cosmetic composition according to claim 18, characterized in that said dextrins have: - at least 5% of 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% - at most 70% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at most 60%, and most preferably at most 50%, - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% - at least 1% of 1-2 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

20. Cosmetic composition according to claim 18, characterized in that said dextrins have: - from 5% to 40% of 1-6 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 42 to 50% of 1-4 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-3 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - 1 to 20% of 1-2 glycosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

Images